The insulin like-growth factor (IGF) system is well recognized to control multiple processes including growth, differentiation, cancer and aging. Our preliminary data includes evidence that genetic variations in the GH- IGF system is involved in human longevity and that the IGF-IGFBP system is a potent modulator of cancer progression in vitro and In vivo. In this project, we propose to utilize an array of unique cell lines and mouse models we have established with focus on IGFBP-deficient mice to determine if they exhibit altered life span or altered stress responsiveness and survival in response to oxidative stress and chemotherapy and to see if fasting results in an additive or antagonistic stress response to toxins. We will also investigate the mechanisms responsible for IGFBP-dependent effects on stress resistance and will examine the differential stress response (DSR) effect in murine genetic models of prostate cancer mated into IGF/IGFBP modified strains. Finally, we plan to investigate if IGF modulating drugs mimic or complement the DSR effects of fasting and diet on stress resistance and longevity in these models. The ultimate goal of this project is to test the hypothesis that lGF-1 and IGFBPs play central roles in the modulation of stress resistance as it relates to aging and diseases of aging. This knowledge can be applied to develop pharmacologic and nutritional interventions that will protect older patients against cancer, chemotherapy and radiotherapy, and other age- dependent diseases caused by endogenous toxins. We will therefore pursue the following specific aims: 1) Investigate the mechanism and differential action of IGFBPs on protection and sensitization of normal and transformed cells in vitro. Our hypothesis is that IGFBPs confer a differential stress resistance effect between primary and cancer cell lines through a dual mechanism involving both IGF-inhibition and direct cellular actions. 2) Define the role of IGFBPs in longevity and in vivo stress resistance through the use of the IGFBPS and IGFBPl knockout mice. 3) Examine the effects of IGF-modulating drugs including IGF-1 receptor blocking-antibodies on stress resistance and longevity in mice. 4) Determine the effects of IGF and IGFBPs on survival in prostate cancer models by mating IGF/IGFBP altered mice into genetic prostate cancer models, testing the progression of prostate cancer. Together, these studies will develop new strategies to understand the molecular mechanisms of cellular protection and apply them to differential protection of normal and cancer cells and the development of strategies to enhance healthy aging

Public Health Relevance

;The insulin-like growth factor (IGF) system is a complex biological pathway that controls cellular and organismal growth and differentiation;and has been linked to aging and longevity on one hand and to cancer progression on the other. We will address important implications of potential therapies that target IGF activity and examine their effects on lifespan and on cancer development in mouse models. Our work will have direct relevance to the health of elderly Americans, as it will pave the way towards safe and effective approaches to enhance lifespan and health-span extension and healthy aging.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG034906-03
Application #
8429466
Study Section
Special Emphasis Panel (ZAG1-ZIJ-5)
Project Start
Project End
Budget Start
2013-03-01
Budget End
2014-02-28
Support Year
3
Fiscal Year
2013
Total Cost
$282,420
Indirect Cost
Name
University of Southern California
Department
Type
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Cohen, Pinchas; Weng, Wayne; Rogol, Alan D et al. (2014) Dose-sparing and safety-enhancing effects of an IGF-I-based dosing regimen in short children treated with growth hormone in a 2-year randomized controlled trial: therapeutic and pharmacoeconomic considerations. Clin Endocrinol (Oxf) 81:71-6
Lee, Amy S (2014) Glucose-regulated proteins in cancer: molecular mechanisms and therapeutic potential. Nat Rev Cancer 14:263-76
Mirisola, Mario G; Taormina, Giusi; Fabrizio, Paola et al. (2014) Serine- and threonine/valine-dependent activation of PDK and Tor orthologs converge on Sch9 to promote aging. PLoS Genet 10:e1004113
Moody, Gordon; Beltran, Pedro J; Mitchell, Petia et al. (2014) IGF1R blockade with ganitumab results in systemic effects on the GH-IGF axis in mice. J Endocrinol 221:145-55
Lee, Changhan; Wan, Junxiang; Miyazaki, Brian et al. (2014) IGF-I regulates the age-dependent signaling peptide humanin. Aging Cell 13:958-61
Zhu, Genyuan; Wang, Miao; Spike, Benjamin et al. (2014) Differential requirement of GRP94 and GRP78 in mammary gland development. Sci Rep 4:5390
Mattson, Mark P; Allison, David B; Fontana, Luigi et al. (2014) Meal frequency and timing in health and disease. Proc Natl Acad Sci U S A 111:16647-53
Hu, Jia; Wei, Min; Mirzaei, Hamed et al. (2014) Tor-Sch9 deficiency activates catabolism of the ketone body-like acetic acid to promote trehalose accumulation and longevity. Aging Cell 13:457-67
Levine, Morgan E; Suarez, Jorge A; Brandhorst, Sebastian et al. (2014) Low protein intake is associated with a major reduction in IGF-1, cancer, and overall mortality in the 65 and younger but not older population. Cell Metab 19:407-17
Verghese, Joe; Annweiler, Cedric; Ayers, Emmeline et al. (2014) Motoric cognitive risk syndrome: multicountry prevalence and dementia risk. Neurology 83:718-26

Showing the most recent 10 out of 27 publications